Lutetium-177 therapy targets prostate-specific membrane antigen (PSMA) to effectively destroy cancer cells, offering superior outcomes for metastatic prostate cancer.
This radiopharmaceutical treatment delivers radioactive substances directly to tumor sites, minimizing impact on surrounding tissues due to short-range radiation emissions.
Collection
[
|
...
]